Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 574,255,424
  • Shares Outstanding, K 2,409,295
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,897 M
  • EBITDA $ 38,236 M
  • 60-Month Beta 0.35
  • Price/Sales 6.10
  • Price/Cash Flow 18.29
  • Price/Book 7.29

Options Overview Details

View History
  • Implied Volatility 21.50% (-0.14%)
  • Historical Volatility 14.74%
  • IV Percentile 88%
  • IV Rank 39.96%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 2) 3.19 (1.34%)
  • Put/Call Vol Ratio 1.12
  • Today's Volume 22,587
  • Volume Avg (30-Day) 30,034
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 369,230
  • Open Int (30-Day) 369,240
  • Expected Range 235.16 to 241.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.68
  • Number of Estimates 8
  • High Estimate 2.85
  • Low Estimate 2.41
  • Prior Year 2.77
  • Growth Rate Est. (year over year) -3.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
203.85 +16.85%
on 01/12/26
240.93 -1.14%
on 02/06/26
+33.81 (+16.54%)
since 01/09/26
3-Month
193.07 +23.37%
on 11/12/25
240.93 -1.14%
on 02/06/26
+44.37 (+22.89%)
since 11/11/25
52-Week
141.50 +68.34%
on 04/09/25
240.93 -1.14%
on 02/06/26
+82.07 (+52.57%)
since 02/11/25

Most Recent Stories

More News
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 6.60 (+2.96%)
AZN : 200.48 (+3.66%)
JNJ : 238.20 (-0.06%)
HELP.NE : 8.7500 (+1.86%)
ABBV : 222.12 (-0.14%)
TAK : 18.26 (+0.87%)
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28 th Annual Global Healthcare Conference on Tuesday, March 10 th , 2026. Management will participate in a Fireside...

JNJ : 238.20 (-0.06%)
5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

XLV : 155.04 (-0.19%)
KO : 76.71 (-0.13%)
JNJ : 238.20 (-0.06%)
PG : 158.55 (-0.33%)
VYM : 155.75 (+0.06%)
IGV.BZ : N/A (N/A)
XLP : 86.90 (-0.29%)
WMT : 126.71 (+0.01%)
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse events i Additional data presented further reinforces...

JNJ : 238.20 (-0.06%)
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

HIMS : 17.46 (+1.28%)
NVO : 48.48 (-1.30%)
JNJ : 238.20 (-0.06%)
LLY : 1,025.50 (+0.05%)
Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from...

JNJ : 238.20 (-0.06%)
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46 th Annual Health Care Conference on Tuesday, March 3 rd , 2026. Management will participate...

JNJ : 238.20 (-0.06%)
What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

XLV : 155.04 (-0.19%)
$SPX : 6,941.81 (-0.33%)
JNJ : 238.20 (-0.06%)
1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

$SPX : 6,941.81 (-0.33%)
JNJ : 238.20 (-0.06%)
KVUE : 18.11 (-1.15%)
Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

KMB : 105.85 (-0.03%)
JNJ : 238.20 (-0.06%)
KVUE : 18.11 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 242.56
2nd Resistance Point 241.53
1st Resistance Point 239.94
Last Price 238.20
1st Support Level 237.32
2nd Support Level 236.29
3rd Support Level 234.70

See More

52-Week High 240.93
Last Price 238.20
Fibonacci 61.8% 202.95
Fibonacci 50% 191.22
Fibonacci 38.2% 179.48
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar